AdAlta links AD-214 results with efficacy thanks to new data

–News Direct–

AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactives Elisha Newell that new data on lead drug candidate AD-214 favourably links preclinical animal studies and Phase I human trial results, providing important dose frequency insights as it moves through the clinic. The findings de-risk the I-body candidates future move into Phase 2 clinical trials and stand to boost confidence as AdAlta progresses partnership discussions. Oldham says the new data is critically important and a credit to AdAltas in-house scientific team.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

AdAlta Ltd

comtex tracking